SCHEMBL20530639

SCHEMBL20530639

COC(=O)c1cccc(-c2cc(C(F)(F)F)ccc2C#N)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.47
MRGPRX4 Q96LA9 1/20 0.46
DGAT2 Q96PD7 1/20 0.45
PDK2 Q15119 1/20 0.45
SDHB P21912 1/20 0.44
TAS2R14 Q9NYV8 1/20 0.42
MAPK14 Q16539 1/20 0.42
AR P10275 1/20 0.42
SYK P43405 1/20 0.42
RAF1 P04049 1/20 0.41
BRAF P15056 1/20 0.41
CES2 O00748 1/20 0.41
PLAU P00749 1/20 0.41
CFTR P13569 1/20 0.41
XDH P47989 1/20 0.41
PTPN1 P18031 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20530644 0.91 XDH (0.48) PTGDR2MRGPRX4DGAT2PDK2SDHB
SCHEMBL7823524 0.81 RAB9A (0.48) PDK2PLAUCA12CA1CA2
SCHEMBL7824610 0.79 PDK2 (0.54) MRGPRX4PDK2SDHBCES2PLAU
SCHEMBL28507787 0.78 CA12 (0.59) MRGPRX4DGAT2PDK2SDHBPLAU
SCHEMBL29917375 0.78 CA12 (0.59) MRGPRX4DGAT2PDK2SDHBPLAU
SCHEMBL2170747 0.77 S1PR3 (0.40) SYK
SCHEMBL8155327 0.77 PTGS2 (0.54) PDK2MAPK14XDHCA12CA1
SCHEMBL23768092 0.77 XDH (0.51) PDK2MAPK14CES2CFTRXDH
SCHEMBL11937452 0.76 AXL (0.49) PDK2PLAUCA12CA1CA2
SCHEMBL1753361 0.76 PTGDR2 (0.70) PTGDR2MRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3609905-B1 PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS HOFFMANN LA ROCHE (CH) 2022-06-08 EP disclosed
US-11091514-B2 Peptide macrocycles and use thereof in the treatment of bacterial infections HOFFMANN-LA ROCHE INC. (US) 2021-08-17 US disclosed
EP-3609905-A1 PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS H. Hoffnabb-La Roche Ag (CH) 2020-02-19 EP disclosed
US-20200040032-A1 PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS HOFFMANN-LA ROCHE INC. (US) 2020-02-06 US disclosed
CN-110494442-A The big ring of peptide and its purposes in treatment bacterium infection HOFFMANN LA ROCHE 2019-11-22 CN disclosed
WO-2018189063-A1 PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS F. HOFFMANN-LA ROCHE AG (CH) 2018-10-18 WO disclosed
EP-3388445-A1 PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS F. Hoffmann-La Roche AG (CH) 2018-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11091514-B2 Peptide macrocycles and use thereof in the treatment of bacterial infections VIP, NPY5R, CXCR3 PTGDR2 1519/4885MRGPRX4 91/4885DGAT2 4879/4885
US-20200040032-A1 PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS VIP, NPY5R, CXCR3 PTGDR2 1519/4885MRGPRX4 91/4885DGAT2 4879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.